Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Runnebaum, Ingo B
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	Active, not recruiting	3	1684	Europe	Ribociclib 200Mg Oral Tablet, Kisqali	West German Study Group, Novartis, Genomic Health®, Inc.	Breast Cancer Female	07/27	07/27
NCT02203760 / 2012-003810-15: Pazopanib Vs. Pazopanib Plus Gemcitabine	Active, not recruiting	2	58	Europe	Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient	North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH	Leiomyosarcoma or Carcinosarcoma	12/24	12/24
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial	Recruiting	N/A	640	Europe, Japan, RoW	Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)	Philipps University Marburg, German Cancer Aid	Cancer of Endometrium Stage I, Cancer of Endometrium Stage II	02/28	02/29